Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;9(9):550-551.
doi: 10.1016/S2213-8587(21)00206-0. Epub 2021 Jul 21.

Dapagliflozin in patients with COVID-19: truth or dare

Affiliations
Comment

Dapagliflozin in patients with COVID-19: truth or dare

Xavier Rossello et al. Lancet Diabetes Endocrinol. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

References

    1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. - PubMed
    1. Rossello X, Yellon DM. A new era in the management of type 2 diabetes: is cardioprotection at long last a reality? Int J Cardiol. 2017;228:198–200. - PubMed
    1. Kosiborod M, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 doi: 10.1016/S2213-8587(21)00180-7. published online July 21. - DOI - PMC - PubMed
    1. Rodríguez-Leor O, Cid-Álvarez B, Pérez de Prado A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Rev Esp Cardiol. 2020;73:994–1002. - PMC - PubMed
    1. Rossello X, González-Del-Hoyo M. Survival analyses in cardiovascular research, part I: the essentials. Rev Esp Cardiol (Engl Ed) 2021 doi: 10.1016/j.rec.2021.06.003. published online June 29. - DOI - PubMed